Article
Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Journal of clinical pharmacology - 1 May 2009
Chen B L, Chen Y, Tu J H, Li Y L, Zhang W, Li Q, Fan L, Tan Z R, Hu D L, Wang D, Wang L S, Ouyang D S, Zhou H H
Abstract excerpt
This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2-phase randomized crossover trial. In each phase, the volunteers are administered a single oral dose of omeprazole 40 mg after pretreatment of either placebo or clopidogrel (300 mg on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
